開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER DR. YOUZHI TONG BY 4,700,000 SHARES

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest developments related to the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company was informed by Dr. Youzhi Tong ("**Dr. TONG**", chairman of the Board, executive Director and chief executive officer of the Company) that he, through his wholly-owned company KT International Investment Limited, purchased 4,700,000 shares of the Company in the open market for a consideration about HK$10.82 million (average transaction price was HK$2.30 per share, purchase price range was from HK$1.89 to HK$2.81 per share) with his own funds from 17 November 2025 to 23 January 2026 (both days inclusive) (the "**Share Purchase**"), representing approximately 0.9425% of the total issued share capital of the Company as at the date of this announcement. Based on the publicly available information to the Company and as far as the Board is aware, after the Share Purchase, the Company still satisfies the requirement of maintaining a sufficient public float.

Dr. Tong expressed his strong confidence about the overall development prospect and commercialization transition of the Group. In compliance with applicable laws and regulatory requirements, Dr. Tong does not rule out that he may further increase his shareholding in the Company depending on the situation after the blackout period (after 26 March 2026).

The Board considers that Dr. TONG's Share Purchase indicates his unswerving confidence in the prospects and the growth potential of the clinical progress and product commercialization of Company's innovative topical drugs, particularly the anti-hair loss and hair regrowth pipeline, and the full recognition of the Company's long-term investment value.

The Group will continuously focus on the field of dermatology, endeavor to push forward the clinical trials of the core dermatology innovative drug KX-826 and GT20029, and strengthen the global brand awareness and competitive edge of the functional cosmetics brand KOSHINÉ to reach more target consumers and enhance brand penetration. Meanwhile, the Group will expedite the registration of KT-939 as a new cosmetic ingredient in China, actively expand the application of KT-939 in the global cosmetic raw materials market, deepen comprehensive collaborations with global cosmetic raw material distributors, brand owner, and manufacturers to explore the global market potential of this innovative ingredient.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman of the Board, Executive Director and
Chief Executive Officer

Hong Kong, 26 January 2026

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*